AR093585A1 - Composicion para liberacion inmediata y prolongada - Google Patents
Composicion para liberacion inmediata y prolongadaInfo
- Publication number
- AR093585A1 AR093585A1 ARP130104308A ARP130104308A AR093585A1 AR 093585 A1 AR093585 A1 AR 093585A1 AR P130104308 A ARP130104308 A AR P130104308A AR P130104308 A ARP130104308 A AR P130104308A AR 093585 A1 AR093585 A1 AR 093585A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- composition according
- active ingredient
- tolterodine
- inner layer
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 abstract 9
- 239000004480 active ingredient Substances 0.000 abstract 7
- 239000010410 layer Substances 0.000 abstract 5
- 239000011159 matrix material Substances 0.000 abstract 4
- 229960004045 tolterodine Drugs 0.000 abstract 4
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 abstract 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 4
- 238000013270 controlled release Methods 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 abstract 3
- 239000002160 alpha blocker Substances 0.000 abstract 2
- 230000001022 anti-muscarinic effect Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000007789 sealing Methods 0.000 abstract 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 abstract 1
- FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical group C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 abstract 1
- 229920001202 Inulin Polymers 0.000 abstract 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 abstract 1
- 240000007472 Leucaena leucocephala Species 0.000 abstract 1
- 229920002774 Maltodextrin Polymers 0.000 abstract 1
- 239000005913 Maltodextrin Substances 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 239000011247 coating layer Substances 0.000 abstract 1
- 229960002845 desmopressin acetate Drugs 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 abstract 1
- 229940029339 inulin Drugs 0.000 abstract 1
- 229940035034 maltodextrin Drugs 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 abstract 1
- 235000010413 sodium alginate Nutrition 0.000 abstract 1
- 239000000661 sodium alginate Substances 0.000 abstract 1
- 229940005550 sodium alginate Drugs 0.000 abstract 1
- -1 swarm Polymers 0.000 abstract 1
- 229960002613 tamsulosin Drugs 0.000 abstract 1
- 229920003169 water-soluble polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3575DE2012 | 2012-11-21 | ||
| IN3947DE2012 | 2012-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR093585A1 true AR093585A1 (es) | 2015-06-10 |
Family
ID=49619947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130104308A AR093585A1 (es) | 2012-11-21 | 2013-11-21 | Composicion para liberacion inmediata y prolongada |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP2922525A1 (h) |
| JP (1) | JP2016500088A (h) |
| KR (1) | KR20150085826A (h) |
| CN (1) | CN104797240A (h) |
| AR (1) | AR093585A1 (h) |
| AU (1) | AU2013349682A1 (h) |
| BR (1) | BR112015011430A2 (h) |
| CA (1) | CA2891365A1 (h) |
| EA (1) | EA201590805A1 (h) |
| HK (1) | HK1213779A1 (h) |
| IL (1) | IL238648A0 (h) |
| IN (1) | IN2015DN03984A (h) |
| MX (1) | MX2015006399A (h) |
| PH (1) | PH12015501096A1 (h) |
| SG (2) | SG11201503913TA (h) |
| TW (1) | TW201422254A (h) |
| WO (1) | WO2014079922A1 (h) |
| ZA (1) | ZA201503603B (h) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3024474T3 (da) | 2013-07-23 | 2022-03-28 | Serenity Pharmaceuticals Llc | Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist |
| KR20150144209A (ko) * | 2014-06-16 | 2015-12-24 | 훼링 비.브이. | 안정화된 데스모프레신 또는 이의 약학적으로 허용가능한 염을 함유 약학 조성물 |
| EP3220942B1 (en) * | 2014-11-20 | 2022-04-27 | Serenity Pharmaceuticals LLC | Compositions comprising low dose desmopressin in combination with an alpha-adrenergic receptor antagonist |
| EP3244881A4 (en) * | 2015-01-12 | 2018-08-15 | Nano Pharmaceutical Laboratories LLC | Layered sustained-release microbeads and methods of making the same |
| EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| RU2018111400A (ru) * | 2015-09-01 | 2019-10-03 | УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Препарат пролонгированного, отсроченного и немедленного высвобождения, способ его получения и применения |
| SG11201805527QA (en) * | 2015-09-30 | 2018-07-30 | Wellesley Pharmaceuticals Llc | Composition for reducing the frequency of urination, method of making and use thereof |
| WO2017058428A1 (en) * | 2015-09-30 | 2017-04-06 | Wellesley Pharmaceuticals, Llc | Composition for reducing the frequency of urination, method of making and use thereof |
| TW201726114A (zh) * | 2015-11-23 | 2017-08-01 | 魏斯理製藥公司 | 降低排尿頻率之組成物、其製備方法、及其應用 |
| BR112018012030A2 (pt) * | 2015-12-18 | 2018-12-04 | Wellesley Pharmaceuticals Llc | composição para redução da frequência de urinação, método de produção e uso da mesma |
| BR112018070415A2 (pt) | 2016-04-21 | 2019-02-05 | Valcuria Ab | composição farmacêutica, kit, inibidor e inibidor para uso |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| US10952959B2 (en) * | 2017-01-11 | 2021-03-23 | Ferring B.V. | Fast disintegrating pharmaceutical composition |
| WO2019039836A2 (ko) * | 2017-08-22 | 2019-02-28 | 아주대학교산학협력단 | 퇴행성 신경질환 치료용 복합 제형 조성물 |
| US12389928B1 (en) * | 2024-10-25 | 2025-08-19 | Mccormick & Company, Inc. | Flavor-changing product |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998003184A1 (en) | 1996-07-19 | 1998-01-29 | Clarke-Garegg, Margaret, A. | Levan derivatives, their preparation, composition and applications including medical and food applications |
| SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
| GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| EP1064938A1 (en) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
| US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| BR0309819A (pt) * | 2002-05-07 | 2005-03-01 | Ferring Bv | Formulações farmacêuticas |
| US8012505B2 (en) | 2003-02-28 | 2011-09-06 | Alk-Abello A/S | Dosage form having a saccharide matrix |
| CN100366294C (zh) | 2004-04-30 | 2008-02-06 | 量子高科（北京）研究院有限公司 | 一种口腔速溶制剂及其生产方法 |
| EP1629834A1 (en) | 2004-08-27 | 2006-03-01 | KRKA, D.D., Novo Mesto | Sustained release pharmaceutical composition of tolterodine |
| WO2007029087A2 (en) | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Controlled release multiple unit formulations |
| US20090192228A1 (en) | 2008-01-28 | 2009-07-30 | Actavis Group Ptc Ehf | Controlled-Release Tolterodine Compositions and Methods |
| US20110217371A1 (en) * | 2008-11-10 | 2011-09-08 | Amorepacific Corporation | Controlled-release microparticles and method of preparing same |
| EP2459180A1 (en) * | 2009-07-31 | 2012-06-06 | Ranbaxy Laboratories Limited | Multi-layered, multiple unit pharmaceutical compositions |
| JO3112B1 (ar) | 2010-03-29 | 2017-09-20 | Ferring Bv | تركيبة دوائية سريعة التحلل |
| AU2011234637B2 (en) | 2010-03-29 | 2013-08-29 | Ferring B.V. | A fast dissolving pharmaceutical composition |
| MX356601B (es) * | 2010-03-30 | 2018-05-29 | Productos Maver S A De C V | Combinación farmacéutica con efecto antimigrañoso, en presentación sólida de liberación diferenciada. |
| US20120135050A1 (en) * | 2010-07-08 | 2012-05-31 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
-
2013
- 2013-11-11 TW TW102140886A patent/TW201422254A/zh unknown
- 2013-11-21 MX MX2015006399A patent/MX2015006399A/es unknown
- 2013-11-21 JP JP2015543424A patent/JP2016500088A/ja active Pending
- 2013-11-21 IN IN3984DEN2015 patent/IN2015DN03984A/en unknown
- 2013-11-21 SG SG11201503913TA patent/SG11201503913TA/en unknown
- 2013-11-21 CN CN201380060349.8A patent/CN104797240A/zh active Pending
- 2013-11-21 EP EP13792703.4A patent/EP2922525A1/en not_active Withdrawn
- 2013-11-21 KR KR1020157015219A patent/KR20150085826A/ko not_active Withdrawn
- 2013-11-21 CA CA2891365A patent/CA2891365A1/en not_active Abandoned
- 2013-11-21 SG SG10201703388TA patent/SG10201703388TA/en unknown
- 2013-11-21 HK HK16101745.8A patent/HK1213779A1/zh unknown
- 2013-11-21 BR BR112015011430A patent/BR112015011430A2/pt not_active Application Discontinuation
- 2013-11-21 EA EA201590805A patent/EA201590805A1/ru unknown
- 2013-11-21 WO PCT/EP2013/074373 patent/WO2014079922A1/en active Application Filing
- 2013-11-21 AR ARP130104308A patent/AR093585A1/es unknown
- 2013-11-21 AU AU2013349682A patent/AU2013349682A1/en not_active Abandoned
-
2015
- 2015-05-05 IL IL238648A patent/IL238648A0/en unknown
- 2015-05-15 PH PH12015501096A patent/PH12015501096A1/en unknown
- 2015-05-21 ZA ZA2015/03603A patent/ZA201503603B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104797240A (zh) | 2015-07-22 |
| SG11201503913TA (en) | 2015-06-29 |
| JP2016500088A (ja) | 2016-01-07 |
| EA201590805A1 (ru) | 2015-11-30 |
| WO2014079922A1 (en) | 2014-05-30 |
| ZA201503603B (en) | 2016-01-27 |
| IN2015DN03984A (h) | 2015-10-02 |
| MX2015006399A (es) | 2015-07-21 |
| SG10201703388TA (en) | 2017-05-30 |
| KR20150085826A (ko) | 2015-07-24 |
| EP2922525A1 (en) | 2015-09-30 |
| HK1213779A1 (zh) | 2016-07-15 |
| PH12015501096A1 (en) | 2015-07-27 |
| BR112015011430A2 (pt) | 2017-07-11 |
| IL238648A0 (en) | 2015-06-30 |
| TW201422254A (zh) | 2014-06-16 |
| CA2891365A1 (en) | 2014-05-30 |
| AU2013349682A1 (en) | 2015-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR093585A1 (es) | Composicion para liberacion inmediata y prolongada | |
| PE20161373A1 (es) | Composiciones de liberacion retardada de linaclotida | |
| HRP20250181T1 (hr) | Spojevi i postupci za ciljanu razgradnju receptora androgena | |
| AR080735A1 (es) | Una composicion farmaceutica de disolucion rapida | |
| AR090898A1 (es) | Una formulacion de farmaco de liberacion retardada | |
| AR104984A1 (es) | Compuestos selectivos para pyy y sus usos | |
| JP2016500088A5 (h) | ||
| MX2018014906A (es) | Composiciones farmaceuticas nasales con un excipiente poroso. | |
| BR112017008993A2 (pt) | métodos e composições especificamente para o tratamento de transtorno de déficit de atenção | |
| AR088232A1 (es) | Composiciones farmaceuticas | |
| AR080736A1 (es) | Composicion farmaceutica de disolucion rapida, usualmente bucodispersable, y proceso para prepararla | |
| JP2013523676A5 (h) | ||
| AR093402A1 (es) | Producto de comicronizacion que comprende acetato de ulipristal | |
| AR092356A1 (es) | Formulacion compuesta para administracion oral que comprende metformina y rosuvastatina y metodo de preparacion de la formulacion | |
| CL2012003341A1 (es) | Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades. | |
| CL2016002318A1 (es) | Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. | |
| CO6400019A1 (es) | Composicion farmaceutica que comprende racetam y carnitina y proceso para su preparacion | |
| PE20151300A1 (es) | Composicion antifungica topica para el tratamiento de onicomicosis | |
| CL2013003744A1 (es) | Compuestos derivados de 2-fenil-n-(piridin-hidroximetil)ciclopropanocarboxamida, moduladores alostéricos positivos (pams) del receptor nicotínico de acetilcolina alfa7; composición farmacéutica; y uso para el tratamiento de una enfermedad seleccionada entre psicosis, esquizofrenia, trastornos cognitivos, entre otros. | |
| MX2019004938A (es) | Cápsula compleja que contiene esomeprazol y método de preparación de esta. | |
| EP2939663A4 (en) | MELT EXTRUDED PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE AND MEDICAMENT FOR ORAL ADMINISTRATION THEREWITH | |
| FI3831385T3 (fi) | Pirlindolienantiomeerien mandelaattisuoloja käytettäviksi lääkinnässä | |
| CL2014002430A1 (es) | Uso del compuesto r-p88 (metabolito activo de iloperidona en su forma enantiomerica r) para tratar una enfermedad psiquiatrica tal como esquizofrenia, trastorno bipolar, depresion, autismo, entre otras, cuando se administra una vez al dia; y composicion farmaceutica que comprende el compuesto r-p88. | |
| MX2019000442A (es) | Derivados de etinilo. | |
| JP2017517574A5 (h) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |